Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)

Authors

  • Sander Kelderman Division of Immunology, Netherlands Cancer Institute (NKI-AVL), Amsterdam
  • Monique K. van der Kooij Department of Clinical Oncology, Leiden University Medical Center, Leiden
  • Alfons J. M. van den Eertwegh Division of Medical Oncology, VU University Medical Center, Amsterdam
  • Patricia M. M. B. Soetekouw Division of Medical Oncology, Maastricht University Medical Center, Maastricht
  • Rob L. H. Jansen Division of Medical Oncology, Maastricht University Medical Center, Maastricht
  • Geke A. P. Hospers Department of Medical Oncology, University Medical Center Groningen, Groningen
  • John B. A. G. Haanen Division of Immunology, Netherlands Cancer Institute (NKI-AVL), Amsterdam; Department of Medical Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam
  • Ellen Kapiteijn Department of Clinical Oncology, Leiden University Medical Center, Leiden
  • Christian U. Blank Division of Immunology, Netherlands Cancer Institute (NKI-AVL), Amsterdam; Department of Medical Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam

DOI:

https://doi.org/10.3109/0284186X.2013.786839

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2013-11-01

How to Cite

Kelderman, S., van der Kooij, M. K., van den Eertwegh, A. J. M., Soetekouw, P. M. M. B., Jansen, R. L. H., Hospers, G. A. P., … Blank, C. U. (2013). Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncologica, 52(8), 1786–1788. https://doi.org/10.3109/0284186X.2013.786839

Issue

Vol. 52 No. 8 (2013): Acta Oncologica

Section

Articles